selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. The company’s most advanced drug candidate, si-544, is a best-in-class Kv1.3 blocker for the treatment of autoimmune diseases.
Investors 1
| Date | Name | Website |
| 16.07.2020 | Global Sou... | globalsour... |
Mentions in press and media 2
| Date | Title | Description | Category | Author | Source |
| 11.03.2021 | Here’s how... | Amsterdam-based The Selection ... | amsterdam ... | Editorial ... | siliconcan... |
| 04.02.2020 | Clinical s... | Inato, a Parisian startup re... | - | Dave Muoio | mobihealth... |